Skip to content
Request Demo
Ferma · White Paper · June 2026

Why BD&L Teams Lose Deals Before the Negotiation Begins

A Methodology for Accelerating BD&L Decision-Making in Life Sciences

Most BD losses are quiet ones. The team was thorough, the asset was right, the analysis was good. But by the time it was finished, someone else had already signed the term sheet.

The information a deal turns on is public. The problem is structural: it is scattered across trials, publications, filings, and competitive sources that were never built to connect. Before any judgment begins, someone spends days reconciling them. The hours meant for judgment go to gathering instead.

This white paper traces why that failure is structural rather than personal, and what the deal cycle looks like when a purpose-built agentic system removes assembly as the bottleneck.

Download the Whitepaper

Platform Coverage

211
K+
Clinical trials indexed and resolved to the asset
489
K+
Conference records across 250+ congresses
15
+
Years of life sciences domain expertise

Ferma WP Illustration

 

what's inside

Screen. Value. Monitor. Compound.

01
Screening at scale
How a BD&L team moved from a universe of 33,575 drugs to five actionable CDH17 ADC targets in a single workflow run, and what the methodology behind that triage looks like.
02
Valuation that holds up
How a sourced rNPV model, built from the bottom up with every input traced, changes the conversation when the steering committee pushes on the number.
03
The monitor that never stops
Why a landscape built last week can already be wrong, and what it costs when the system stops watching. Across 13,000+ trial readouts, one result moved early-stage biotech by 6% on average, with a tail running to a five-fold gain.
04
Conviction that compounds
Why firms winning on speed are building institutional memory the competition cannot recreate on demand, and what that looks like as a structural advantage rather than a tactical one.
Learn more

About Ferma

Ferma is the AI-native intelligence platform for life sciences, a business unit of ZoomRx, trusted by 100+ leading biopharma companies across the world and built on 15+ years of life-sciences domain expertise. Ferma's Agentic Workflows turn the research, synthesis, and delivery of decision-ready intelligence into finished, fully cited deliverables across BD&L, Competitive Intelligence, New Product Planning, and beyond, built on coverage spanning clinical trials, conferences, regulatory filings, publications, and native-language China sources. SOC 2 Type II certified.

Learn more